Applied science may yield more translational research publications than basic science

While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.

The NIH prioritizes funding for translational research, or studies that apply findings from basic science to promote human health and well-being. Since there are many different definitions of translational research and important milestones in biomedical research have yet to be defined, it is difficult to track and quantify its progress.

In their new study, Han and colleagues investigated the amount of translational research produced from three types of NIH-funded research awards between 2008 and 2014: basic and applied research grants in the behavioral and social sciences, and the Clinical and Translational Science Award, a program that specifically targets translational research. They analyzed all publications produced from those 6,387 awards and they determined what percentage of those publications could be classified as translational research. From this analysis, the researchers found that 3.9% of publications produced by basic research awards, 7.4% produced by applied research awards, and 13.4% of the CTSA program publications were translational.

The researchers' analysis of NIH-funded behavioral and social sciences research demonstrates a progression toward increased translational research as they moved across the research spectrum from basic science to applied science, with the targeted translational research program yielding the highest number of translational research publications. The researchers suggest that translational research can happen at any stage of research, with increasing frequency in applied science, and that targeted translational research programs such as CTSA appear to be effective at promoting the translation of basic and applied sciences into medical practices and meaningful health outcomes.

Xueying Han says: "Our findings suggest that translational research can happen at any stage along the research continuum, and that targeted translational research programs, such as the Clinical and Translational Science Award Program, appear to be effective at increasing the translation of basic and applied research to health outcomes."

Xueying Han, Sharon R Williams, Brian L Zuckerman.
A snapshot of translational research funded by the National Institutes of Health (NIH): A case study using behavioral and social science research awards and Clinical and Translational Science Awards funded publications.
PLoS ONE 13(5). doi: 10.1371/journal.pone.0196545.

Most Popular Now

Amgen and the Amgen Foundation commit up to $12.5 …

Amgen (NASDAQ:AMGN) and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in...

Novartis and life sciences companies commit expert…

Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics...

AstraZeneca to donate 9 million face masks to supp…

AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZ...

Roche response to COVID-19 pandemic

Roche Group (SIX: RO, ROG; OTCQX: RHHBY), provided an update on the various actions the company is taking to address the COVID-19 pandemic. On March 19, 2020, Roche co...

Singapore modelling study estimates impact of phys…

A new modelling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing [2] interventions, comprising quarantine (f...

CAR macrophages go beyond T cells to fight solid t…

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Pere...

FDA approves first plasma therapy for Houston Meth…

Houston Methodist received FDA approval Saturday to become the first academic medical center in the nation to transfuse donated plasma from a recovered COVID-19 patient i...

Consignment of 30 million hydroxychloroquine table…

Novartis announced that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Depar...

Experimental AI tool predicts which COVID-19 patie…

An artificial intelligence tool accurately predicted which patients newly infected with the COVID-19 virus would go on to develop severe respiratory disease, a new study ...

Vivli to launch a portal for sharing data from COV…

In a visible sign of data sharing leadership, Vivli, the Center for Clinical Research Data has committed to serving the open science community through the launch of a COV...

Roche initiates Phase III clinical trial of Actemr…

Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical tria...

Novartis commits to donate up to 130 million doses…

Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and...